Company profile
EVOLUS, INC.
NASDAQ:EOLSBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| JEUVEAU | approved | $74.5MQ2 2026 | 0 | — |
| BOTULINUM TOXIN | phase3 | — | 2 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02334436 | phase3 | completed | 2015-01-01 | 2015-09-01 | Evolus, Inc. | A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002 |
| NCT02334423 | phase3 | completed | 2015-01-01 | 2015-12-01 | Evolus, Inc. | A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001 |
| NCT02184988 | phase2 | completed | 2014-08-01 | 2015-12-01 | Evolus, Inc. | Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines |
| NCT02428608 | phase2 | completed | 2015-05-01 | 2016-10-01 | Evolus, Inc. | Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006 |
| NCT05320393 | phase2 | completed | 2022-03-30 | 2023-05-22 | Evolus, Inc. | Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 761085 | 2019-02-01 | BLA | EVOLUS INC. | |||||
Loading… | ||||||||